GTx, Inc. (Nasdaq: GTXI) announced today that it is sponsoring a symposium on Muscle Wasting in Non-Small Cell Lung Cancer Patients at 12:00 pm eastern daylight time on September 22, 2012, at the Hilton Back Bay Hotel in Boston Massachusetts. Stefan Anker, MD, PhD will introduce an esteemed faculty of experts, including Jeffrey Crawford, MD, Carla Prado, PhD, Richard Gralla, MD, and James D. Dalton, PhD, who will discuss muscle wasting in lung cancer patients and the role of patients’ quality of life when addressing cancer care. The science behind using selective androgen receptor modulators (SARMs) to address muscle wasting in cancer patients will be presented, as well as GTx’s clinical trial design for its ongoing pivotal Phase III clinical trials of enobosarm (a SARM developed by GTx) for the prevention and treatment of muscle wasting in non-small cell lung cancer patients.

GTx’s symposium is being held in conjunction with the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) scientific conference on “Cancer Cachexia: Molecular Mechanisms and Therapeutic Approaches” which also will be held at the Hilton Back Bay Hotel September 21st through 23rd, 2012. The faculty and scientific committee for the conference are experts in the field of cachexia, sarcopenia and palliative care and will review the mechanisms of cachexia and weight loss, therapeutic targets for the management of cachexia, and current basic science and clinical research. The SCWD is recognized by both national and international cancer and palliative care researchers for its strong scientific expertise and leadership in the field.

In addition to the symposium, GTx will be presenting data from its Phase IIb clinical study of enobosarm Saturday, September 22nd in the Maverick A&B rooms of the Hilton Back Bay Hotel. The first presentation entitled, “In a Phase IIb Trial in Cancer Patients with Muscle Wasting, Enobosarm Improves Physical Function in Both Hypogonadal and Eugonadal Subjects,” will be presented by Mitchell S. Steiner, MD, GTx’s CEO. The second presentation entitled, “The Effect of Enobosarm on Physical Function in Cancer Patients with < or ≥5% Weight Loss in a Phase IIb Trial”, will be presented by James D. Dalton, PhD, GTx’s Chief Scientific Officer.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions.